NASDAQ:ATRC - AtriCure Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $29.51 +0.20 (+0.68 %) (As of 05/24/2019 04:00 PM ET)Previous Close$29.31Today's Range$29.28 - $29.6252-Week Range$23.61 - $36.49Volume38,194 shsAverage Volume233,774 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/ABeta0.29 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio. Receive ATRC News and Ratings via Email Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC Previous Symbol CUSIP04963C20 CIK1323885 Webhttp://www.atricure.com/ Phone513-755-4100Debt Debt-to-Equity Ratio0.19 Current Ratio4.37 Quick Ratio3.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$201.63 million Price / Sales5.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.20 per share Price / Book4.76Profitability EPS (Most Recent Fiscal Year)($0.94) Net Income$-21,140,000.00 Net Margins-7.98% Return on Equity-14.35% Return on Assets-9.41%Miscellaneous Employees620 Outstanding Shares38,623,000Market Cap$1.14 billion Next Earnings Date8/7/2019 (Estimated) OptionableOptionable AtriCure (NASDAQ:ATRC) Frequently Asked Questions What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." How were AtriCure's earnings last quarter? AtriCure Inc. (NASDAQ:ATRC) released its quarterly earnings data on Thursday, February, 28th. The medical device company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The medical device company had revenue of $52.89 million for the quarter, compared to the consensus estimate of $51.62 million. AtriCure had a negative net margin of 7.98% and a negative return on equity of 14.35%. View AtriCure's Earnings History. When is AtriCure's next earnings date? AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for AtriCure. What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY 2019 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $222-228 million, compared to the consensus revenue estimate of $225.84 million. What price target have analysts set for ATRC? 7 brokers have issued 1-year target prices for AtriCure's shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate AtriCure's share price to reach $35.8333 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for AtriCure. What is the consensus analysts' recommendation for AtriCure? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure. What are Wall Street analysts saying about AtriCure stock? Here are some recent quotes from research analysts about AtriCure stock: 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (4/26/2019) 2. Needham & Company LLC analysts commented, "ATRC shares are down 14% over the last month, versus a 3% decline in the Russell 2000, partly due to concerns about transcatheter aortic valve replacement (TAVR) cannibalizing surgical aortic valve replacement (SAVR) due to the expected low-risk TAVR indications, in our view. While ATRC doesn’t sell SAVR devices, its Open-Heart Ablation products are used in concomitant SAVR procedures. But we believe that ATRC’s US SAVR exposure is only ~7% of sales and that while some SAVR cannibalization is likely, the impact should be limited by several factors. And given strong growth from ATRC’s Convergent procedure, AtriClip products, and Therapy products, we think its SAVR exposure will become less important over time. We view the recent weakness as a buying opportunity and reiterate our Buy rating." (3/28/2019) 3. BTIG Research analysts commented, "Neutral ATRC reported full Q4 results last week while we were hosting our annual Snowbird conference. Since the company pre-announced top-line results in early January, there were few surprises accompanying the formal Q4 print. On the call itself, the company highlighted several positive drivers including 1) continued outperformance in the AtriClip platform, 2) opportunities within a new pain management vertical, and 3) building society support with the recent STS endorsement of ablation courses being a constructive step. On the flip side, there were a few disappointing updates: 1) the lack of a public data release of CONVERGE until 2020, 2) substantially higher R&D and SG&A expenses than the Street modeled for FY19 and 3) some lumpiness in the China business (there were no orders in the quarter) though we expect the new distributor arrangement will add more consistency." (3/5/2019) Has AtriCure been receiving favorable news coverage? News coverage about ATRC stock has been trending positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AtriCure earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO), Atrion (ATRI), Irhythm Technologies (IRTC), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII) and K2M Group (KTWO). What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include Amgen (AMGN), Gilead Sciences (GILD), AbbVie (ABBV), Neurocrine Biosciences (NBIX), Intel (INTC), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Abbott Laboratories (ABT), Allergan (AGN) and CVS Health (CVS). Who are AtriCure's key executives? AtriCure's management team includes the folowing people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)Mr. Douglas J. Seith, Chief Operating Officer (Age 53)Mr. Salvatore Privitera, Chief Technology Officer (Age 52)Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41) Who are AtriCure's major shareholders? AtriCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), BlackRock Inc. (7.65%), Wellington Management Group LLP (6.74%), Loomis Sayles & Co. L P (2.36%), Neuberger Berman Group LLC (1.90%) and Peregrine Capital Management LLC (1.89%). Company insiders that own AtriCure stock include B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure. Which major investors are selling AtriCure stock? ATRC stock was sold by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, Federated Investors Inc. PA, Wellington Management Group LLP, BlackRock Inc., AlphaOne Investment Services LLC, Morgan Stanley, Parametric Portfolio Associates LLC and Oxford Asset Management LLP. Company insiders that have sold AtriCure company stock in the last year include Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure. Which major investors are buying AtriCure stock? ATRC stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Assenagon Asset Management S.A., Wasatch Advisors Inc., BNP PARIBAS ASSET MANAGEMENT Holding S.A., Renaissance Technologies LLC, Martingale Asset Management L P, Peregrine Capital Management LLC and Royce & Associates LP. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure. How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $29.51. How big of a company is AtriCure? AtriCure has a market capitalization of $1.14 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe. What is AtriCure's official website? The official website for AtriCure is http://www.atricure.com/. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100. MarketBeat Community Rating for AtriCure (NASDAQ ATRC)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 384 (Vote Outperform)Underperform Votes: 269 (Vote Underperform)Total Votes: 653MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Bid-Ask Spread Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.